New stock news | Sino Medical Sciences Technology Inc. (688108.SH) intends to list in Hong Kong. The China Securities Regulatory Commission requires clarification on whether the operational business involves advanced brain-computer interface technology and specific details.

On July 10, the China Securities Regulatory Commission announced the disclosure of supplementary materials required for overseas issuance and listing filings (July 6, 2026 to July 10, 2026). The CSRC requires Sino Medical Sciences Technology Inc. to provide additional explanations on the specific implementation of regulatory procedures such as overseas investments and foreign exchange registration related to the establishment of overseas subsidiaries, and to issue conclusive opinions on compliance. The company needs to provide information on whether its operations involve advanced brain-machine interface technology and specific details. According to the disclosure on May 27 by the Hong Kong Stock Exchange, Sino Medical Sciences Technology Inc. (688108.SH) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CMB International as its sole sponsor. In addition, the CSRC requires Sino Medical Sciences Technology Inc. to provide additional explanations on the following matters, to be verified by lawyers and to provide clear legal opinions: Explanation: According to the "Guidelines for the Application of Regulatory Rules - Overseas Issuance and Listing Class No. 2: Guidelines for Material Contents and Formats", detailed explanations are required on the establishment of the company, changes in share capital and shareholders since establishment, including but not limited to capital increases, share transfers, and related payments; Lawyers should provide verification opinions on whether there are related relationships among shareholders, whether there are entrusted shareholdings or other forms of interest transfer, and whether the establishment and past equity changes of the issuer are legal and compliant. Explanation: Are participants in the employee stock incentive plan employees of the company, the specific composition and roles of participants, whether there are relationships between participants and other shareholders, directors, supervisors, or senior management of the issuer; whether there are external individuals, if so, provide verification explanations in accordance with the relevant requirements in the "Guidelines for the Application of Regulatory Rules - Overseas Issuance and Listing Class No. 2"; whether participants holding incentive shares after leaving the company comply with previous agreement terms, whether there are disputes or potential disputes; the fairness of the entry price of the stock incentive plan, the reasons and backgrounds of external individuals entering the plan, entry prices, valuation basis, funding sources, whether there are interest transfers if prices are similar to those of employees; and provide clear conclusive opinions on the legality and compliance of implemented stock incentive plans and post-listing options. Explanation: Basis for determining the controlling shareholder and the actual controller of the company, provide reasons and rationality based on the shareholding proportions of each shareholder. Whether the business scope and actual operations of the company and its subsidiary enterprises involve restrictions or prohibitions in the "Special Administrative Measures on Foreign Investment Access (Negative List) (2024 Edition)", and whether they continue to meet foreign investment entry requirements after this issuance and listing. It is reported that Sino Medical Sciences Technology Inc. is a global company specializing in the field of interventional medical devices, committed to meeting unmet clinical needs and providing solution-oriented, clinically validated solutions. Founded by Dr. Sun Jianhua in 2007, the company has established a global operating layout covering research and development, manufacturing, and commercialization, with operations in approximately 30 countries and regions.